Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is BIO's Director for Health Communications, where he handles communications on public policy issues affecting members of BIO's health and emerging company sections. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He has a Master's degree in Public Relations and Corporate Communications from Georgetown University.

Latest Posts

Tomorrow: From Volume to Value: Designing a Patient-Centered Healthcare System (Webcast)

new-bio-logo

Tomorrow at the Newseum, The Hill will be hosting a live discussion about the transition from volume-based to value-based care. A live webcast will be available for the event, which begins at 8:30 am ET. Last week, Jim Robinson, President of Astellas Pharma US, shared his thoughts in a related op-ed at The Hill. Biopharmaceutical innovation is transforming what it means to be a patient battling some of our most difficult diseases, such as cancer, Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post

Senators Talent and Graham: Time to Act on Threat of Biological Terrorism

ebola

Last Friday in the St. Louis Post-Dispatch, Former Senators Jim Talent and Robert Graham wrote about the growing threat of biological attacks and threats and steps our nation can take to help prepare for them, including some of the recommendations in the report of the Blue Ribbon Study Panel on Biodefense, on which BIO President and CEO Jim Greenwood serves. The first step is to stockpile the medical countermeasures that will be necessary in the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Washington Post: Gene Therapies Offer “Dramatic Promise”

stethoscope

Yesterday’s Washington Post has an in-depth article about gene therapy, a type of therapeutic intervention which alters the underlying DNA responsible for producing certain diseases. The technology is enjoying a resurgence, fueled by some stunningly positive results in certain clinical trials recently. The authors begin with the story of 23 year old Allison Corona, who suffers from a congenital diseases that left her legally blind at age four. After receiving a gene therapy treatment: The world Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

A National Blueprint for Biodefense Released Today

ebola

A major report was released today detailing findings and recommendations to improve the U.S. biodefense readiness. “A National Blueprint for Biodefense: Leadership and Major Reform Needed to Optimize Efforts” was authored by the Blue Ribbon Study Panel on Biodefense, on which BIO President and CEO Jim Greenwood serves. The panel is co-chaired by former Sen. Joe Lieberman and former Gov. Tom Ridge. Other panelists include former Secretary of Health and Human Services Donna Shalala, former Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: ,

Biotech Policy Outlook at #BIF15: 21st Century Cures, IPR, TPP, and PDUFA VI

BIO Investor Forum

To even the most casual observer, 2015 has been a big year in the biotech industry, particularly in Congress and in other venues wherein public policies that affect the sector take shape. Given the importance of the policy environment in determining how successful companies in our industry can be at delivering new cures and treatments to patients – and a return to the investors who finance their activities – we decided that a close look Read More >

Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,